|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007785,
umls-concept:C0026336,
umls-concept:C0040018,
umls-concept:C0087111,
umls-concept:C0205494,
umls-concept:C0332161,
umls-concept:C0392756,
umls-concept:C0456389,
umls-concept:C0596988,
umls-concept:C0948008,
umls-concept:C1274040,
umls-concept:C1522424
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-5-30
|
|
pubmed:abstractText |
Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E217A (WE) is antithrombotic without hemostasis impairment in primates. Therefore, we investigated the outcome of WE-treated experimental ischemic stroke in mice.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/EB009682,
http://linkedlifedata.com/resource/pubmed/grant/HL049413,
http://linkedlifedata.com/resource/pubmed/grant/HL058141,
http://linkedlifedata.com/resource/pubmed/grant/HL073813,
http://linkedlifedata.com/resource/pubmed/grant/HL093140,
http://linkedlifedata.com/resource/pubmed/grant/L095315,
http://linkedlifedata.com/resource/pubmed/grant/R01 EB009682-01,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL049413-06,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL058141-03,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL073813-01,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL073813-10,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL093140-01,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL093140-05,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL101972-01A1,
http://linkedlifedata.com/resource/pubmed/grant/R01 NR003521-20,
http://linkedlifedata.com/resource/pubmed/grant/R01HL101972
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1524-4628
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1736-41
|
|
pubmed:dateRevised |
2011-10-18
|
|
pubmed:meshHeading |
pubmed-meshheading:21512172-Animals,
pubmed-meshheading:21512172-Anticoagulants,
pubmed-meshheading:21512172-Brain Ischemia,
pubmed-meshheading:21512172-Cerebral Infarction,
pubmed-meshheading:21512172-Disease Models, Animal,
pubmed-meshheading:21512172-Hemostasis,
pubmed-meshheading:21512172-Humans,
pubmed-meshheading:21512172-Infarction, Middle Cerebral Artery,
pubmed-meshheading:21512172-Laser-Doppler Flowmetry,
pubmed-meshheading:21512172-Male,
pubmed-meshheading:21512172-Mice,
pubmed-meshheading:21512172-Mice, Inbred C57BL,
pubmed-meshheading:21512172-Mutation,
pubmed-meshheading:21512172-Stroke,
pubmed-meshheading:21512172-Thrombin,
pubmed-meshheading:21512172-Tissue Plasminogen Activator,
pubmed-meshheading:21512172-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
|
|
pubmed:affiliation |
Department of Biomedical Engineering, Oregon Health & Science University, 3303 SW Bond Ave, Portland, OR 97239, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
